Sooma Medical tDCS
Trusted by professionals worldwide
Sooma is a world-leading provider of effective brain stimulation treatments for psychiatric and neurological disorders. The therapies are drug-free, and can be used either as a first-line of treatment or to bring additive effects to other forms of treatment. Our therapies are used by healthcare professionals in 35 countries worldwide to treat patients, with proven results of efficacy.
Sooma Depression Therapy is a solution for bifrontal transcranial direct current stimulation. It includes a stimulation system and a remote patient monitoring software.
The Home Kit includes all you need for administering Sooma Depression Therapy efficiently both in the clinic or at the patients’ home.
The stimulator unit comes with 2 mA current and 30-minute stimulation duration as default parameters. This current is applied through the DLPFC using proprietary Sooma Comfort accessories.
The solution is Class IIa medical device indicated for treatment of major depressive disorder. It is built to the highest industry standards in Finland.
Cost for the complete tDCS is £2,995.00 plus VAT.
For more information and clinical reference and webinars please visit:
Sooma | An effective therapy for depression and chronic pain (soomamedical.com)
New regulations for Neurostimulation Devices arrive in Europe. What's changed and, how could it impact you?
On the first of December, 01/12/2022, the European Parliament implemented new regulations on medical devices across the union (EU 2022/2347). With these new restrictions, brain stimulation devices lacking medical claims are automatically assigned the highest-risk category (Class III), requiring a stringent regulatory process that effectively bars ineffective or fraudulent devices from the European market.
This change does not impact Sooma, Sooma's customers, or patients using Sooma devices. Since day one, our focus has been on medical indications and clinical therapy in full compliance with regulators. Thus, Sooma devices will continue to maintain their Class IIa status. We welcome this change as it prioritises the safety of those prescribing and, most importantly, those receiving treatment.
For doctors prescribing or patients using neurostimulation products other than Sooma Therapy devices: You can find more information on the new regulations and methods for ensuring that your device is not affected in our latest blog post.
